Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
暂无分享,去创建一个
R A Kyle | R. Kyle | S. Rajkumar | S V Rajkumar | R. Kyle
[1] T. Therneau,et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.
[2] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[3] W. Lewis,et al. Multiple myeloma: diagnosis and treatment. , 2008, American family physician.
[4] Bart Barlogie,et al. Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.
[5] M. Dimopoulos,et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[6] P. Loehrer,et al. International Staging System for Multiple Myeloma , 2006 .
[7] T. Therneau,et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.
[8] R. Bataille,et al. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. , 1983, British journal of haematology.
[9] Zhaoming Ye,et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma , 1996 .
[10] T. Therneau,et al. POEMS syndrome: definitions and long-term outcome. , 2003, Blood.
[11] C. Bastard,et al. Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.
[12] B. Barlogie,et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.
[13] P. Gobbi,et al. Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance? , 2005, Clinical Cancer Research.
[14] A. Dispenzieri,et al. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. , 2006, Mayo Clinic proceedings.
[15] A. Rossi,et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[17] T. Therneau,et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system , 2008, Leukemia.
[18] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[19] R. Bataille,et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.
[20] T. Therneau,et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. , 2006, Blood.
[21] Terry M Therneau,et al. Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.
[22] B. Barlogie,et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma , 2002, British journal of haematology.
[23] T. Therneau,et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.
[24] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[25] M. Beksac,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[26] P. Richardson,et al. Clinically relevant end points and new drug approvals for myeloma , 2008, Leukemia.
[27] M. Dimopoulos,et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. , 2000, Blood.
[28] Lust,et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.